2seventy bio, Inc.
TSVT
$0.22
Change (1 day)
$6.40
Year High
$2.78
Year Low
Categories
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.
P/S ratio for 2seventy bio, Inc. (TSVT)
P/S ratio as of 2023: 2.10
According to 2seventy bio, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 2.10. At the end of 2022 the company had a P/S ratio of 3.65.
P/S ratio history for 2seventy bio, Inc. from 2018 to 2023
P/S ratio at the end of each year
| Year | P/S ratio |
|---|---|
| 2023 | 2.10 |
| 2022 | 3.65 |
| 2021 | 11.09 |
| 2020 | 1.29 |
| 2019 | 7.24 |
| 2018 | 5.88 |